Published in:
01-12-2013 | Original Article
Severe intestinal toxicity after stereotactic ablative radiotherapy for abdominopelvic malignancies
Published in: International Journal of Colorectal Disease | Issue 12/2013
Login to get accessAbstract
Purpose
The purpose of this study is to identify the predictors for severe intestinal toxicity (IT) in patients with abdominopelvic malignancies treated with three fractions of stereotactic ablative radiotherapy (SABR).
Methods
From 2001 to 2011, 202 patients with abdominopelvic malignancies were treated with curative-intent SABR. Among these, we retrospectively reviewed the clinical records of 55 patients with the presence of the intestine that received a dose ≥20 % of the prescribed dose. The total dose ranged from 33 to 60 Gy in three fractionations (median dose, 45 Gy). We analyzed the clinical and dosimetric parameters for severe IT ≥ grade 3 according to the National Cancer Institute Common Toxicity Criteria v4.0: V
20–35 (volume of the intestine that received xGy) and D
max (maximum point dose).
Results
Severe IT was found in six patients (the median time, 3 months). V
25 was the best dosimetric predictor for severe IT (P = 0.004). With V
25 ≤ 20 ml, severe IT decreased from 50 to 4 %. SABR duration was the best clinical predictor. Severe IT decreased in patients who received SABR at 4–8 days than on three consecutive days (0 vs. 18 %, P = 0.037).
Conclusions
Following three fractions of SABR, V
25 is a valuable predictor of severe IT. And SABR would be conducted with a treatment interval of at least 48 h if possible.